Semantic Scholar uses AI to extract papers important to this topic.
Background High‐dose chemotherapy plus autologous stem‐cell transplantation has been the standard treatment for newly diagnosed… Expand BACKGROUND
Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and… Expand BACKGROUND
Intravenous injection is the standard administration route of bortezomib; however, subcutaneous administration is an… Expand This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients… Expand BACKGROUND
The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan… Expand PURPOSE
Evaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of… Expand BACKGROUND
This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had… Expand The dipeptide boronic acid analogue VELCADE™ (Bortezomib; formerly known as PS-341, LDP-341 and MLM341) is a potent and selective… Expand In a phase 2 open‐label study of the novel proteasome inhibitor bortezomib, 54 patients with multiple myeloma who had relapsed… Expand BACKGROUND
Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has been shown in preclinical and phase 1… Expand